255 related articles for article (PubMed ID: 8701935)
1. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
2. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases.
Bartl R; Frisch B; Fateh-Moghadam A; Kettner G; Jaeger K; Sommerfeld W
Am J Clin Pathol; 1987 Mar; 87(3):342-55. PubMed ID: 3825999
[TBL] [Abstract][Full Text] [Related]
3. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.
Terpstra WE; Lokhorst HM; Blomjous F; Meuwissen OJ; Dekker AW
Br J Haematol; 1992 Sep; 82(1):46-9. PubMed ID: 1419801
[TBL] [Abstract][Full Text] [Related]
4. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.
Witzig TE; Gertz MA; Lust JA; Kyle RA; O'Fallon WM; Greipp PR
Blood; 1996 Sep; 88(5):1780-7. PubMed ID: 8781435
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic implications of myeloma staging.
Durie BG; Bataille R
Eur J Haematol Suppl; 1989; 51():111-6. PubMed ID: 2697583
[TBL] [Abstract][Full Text] [Related]
7. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow histology and serum beta 2 microglobulin in multiple myeloma--a new prognostic strategy.
Bartl R; Frisch B; Diem H; Mündel M; Fateh-Moghadam A
Eur J Haematol Suppl; 1989; 51():88-98. PubMed ID: 2697597
[TBL] [Abstract][Full Text] [Related]
9. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
[TBL] [Abstract][Full Text] [Related]
10. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
11. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bone marrow histology in multiple myeloma.
Subramanian R; Basu D; Dutta TK
Indian J Cancer; 2009; 46(1):40-5. PubMed ID: 19282565
[TBL] [Abstract][Full Text] [Related]
13. Serum beta 2-microglobulin, serum creatinine and bone marrow plasma cells in benign and malignant monoclonal gammopathy.
Morell A; Riesen W
Acta Haematol; 1980; 64(2):87-93. PubMed ID: 6159767
[TBL] [Abstract][Full Text] [Related]
14. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
[TBL] [Abstract][Full Text] [Related]
15. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.
Niemöller K; Jakob C; Heider U; Zavrski I; Eucker J; Kaufmann O; Possinger K; Sezer O
J Cancer Res Clin Oncol; 2003 Apr; 129(4):234-8. PubMed ID: 12700896
[TBL] [Abstract][Full Text] [Related]
17. Histomorphology of multiple myeloma on bone marrow biopsy.
Singhal N; Singh T; Singh ZN; Shome DK; Gaiha M
Indian J Pathol Microbiol; 2004 Jul; 47(3):359-63. PubMed ID: 16295424
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
19. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
20. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma.
Sezer O; Niemöller K; Jakob C; Zavrski I; Heider U; Eucker J; Kaufmann O; Possinger K
Ann Hematol; 2001 Oct; 80(10):598-601. PubMed ID: 11732871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
